This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring
THE SPRINGTIME PARTNERING EVENT
March 18–20, 2024 | Barcelona, SpainMarch 26–27, 2024 | Digital Partnering

Lempo Therapeutics Ltd.

Profile

Lempo Therapeutics is a pre-clinical biotech company, pioneering a paradigm shift in the modification of the innate immune system to effectively combat autoimmune and life threatening progressive diseases. Our patented novel treatment uses ex-vivo stem cells gene-editing technique to minimize the collateral damage caused by the immune system as a result of its activity. By doing so, we expect to significantly attenuate the progression of diseases. This approach has already been proven to work in animal models of Alzheimer's Disease, Multiple Sclerosis, cardiovascular diseases, and more. We focus first on treating Pulmonary Arterial Hypertension (PAH) and ANCA-associated Vasculitis(AAV), both rare, devastating diseases with no available cure and poor prognosis.